Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Sandoz's Multi-Switch Biosimilar Trials: A View To Interchangeability?

Jul 22 2016

• By Derrick Gingery

SandozNorvatisDiv_1200

Related Content

<em>Zarxio</em> Syringe’s Limitations May Delay Decision On <em>Neupogen</em> Interchangeability

Jun 15 2015

FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared

Jun 15 2015

Biosimilar Sponsors May Seek Interchangeability Before FDA Sets Rules

Apr 24 2015

Biosimilar Advisory Committee Features Actual Debate About Biosimilarity

Jul 14 2016

Biosimilar Non-Medical Switching: Advocacy Groups, FDA Advisors Push For Action

Jul 15 2016

Biosimilar Advisory Committee Reviews: Necessity Or Nuisance?

Jul 20 2016

Edging Toward Interchangeability in Biosimilars

Jul 20 2016

Biosimilars' Pediatric Pressures Could Push Them Toward Interchangeability

Jul 15 2016

Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway

Jul 13 2016

Related Companies

Novartis AG

Amgen, Inc.

AbbVie Inc.

Additional Topics

United States Policy Biosimilars Advisory Committees Drug Review Regulation BioPharmaceutical

More from Policy & Regulation

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window